Preliminary Program

This high-impact, 90-minute educational program will focus on the latest evidence for optimizing treatments for Newly Diagnosed and Relapsed/Refractory patients, including choices for immunotherapy. Key concepts will be covered in presentations by senior faculty, along with practice-relevant case-based discussions.

This high-impact, 90-minute educational program will focus on the latest evidence for optimizing treatments for Newly Diagnosed and Relapsed/Refractory patients, including choices for immunotherapy. Key concepts will be covered in presentations by senior faculty, along with practice-relevant case-based discussions.

Are you a community physician treating patients with multiple myeloma?

If so, this workshop is for you!

Because of the limited experience with T cell redirection treatment strategies in the real world and especially bispecific T cell engagers and CAR T therapies among oncologists and health care professionals outside CAR T administering centers, there is a gap in the understanding, management and utilization of these therapies in patients that might benefit from these types of treatments. As more drug products become available through commercial and research routes, there will be a greater need  for a close partnership between the centers where these treatments are administered and the smaller community centers where the vast majority of oncology patients are typically followed and receive the bulk of their treatments. There is an urgent need to bridge this knowledge gap and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engagers and CAR T therapies among health care professionals

IMS is pleased to announce that the 4th Annual Workshop on Genomics will take place from July 10-11, 2026 in Warsaw, Poland.

The 4th Annual IMS Workshop on Genomics will be held on July 10–11, 2026, in Warsaw, Poland, and will focus on the biology, identification, and treatment of functional and ultra-high-risk multiple myeloma—an area of significant unmet need. Despite overall improvements in outcomes, a subset of patients continues to experience poor prognoses even with intensive therapy. Defining these patients, elucidating the drivers of their disease, and developing more effective treatment strategies remain urgent priorities.

The first day will examine the determinants of functional high-risk disease from multiple perspectives. Sessions will address how functional high risk should be defined, limitations of current frameworks, and the genomic basis of high-risk disease—including performance of existing classifiers, co-occurrence of risk features, and practical considerations for management from induction through relapse, including extramedullary disease and plasma cell leukemia. We will also explore and define an ultra-high-risk population that may have the highest risk and shorter survival outcome despite all current therapies.

The second day will broaden the discussion to emerging areas of research. Presentations will highlight new genomic data encompassing both myeloma cells and the tumor microenvironment. Additional sessions will explore novel therapeutic vulnerabilities, including RNA-targeted approaches, oncogenic pathway dependencies, and epigenetic strategies relevant to high-risk disease. Novel targets and theories will be discussed.

Across both days, the workshop will promote active dialogue among basic scientists, translational investigators, and clinicians, with integrated panel discussions designed to foster debate, refine key questions, and build consensus.

Mark your calendars for the 23rd IMS Annual Meeting in Glasgow, Scotland.

The International Myeloma Society Annual Meeting is the defining annual meeting in myeloma.

More details on the program, abstract submissions, registration and housing will be available soon.